Mucocutaneous Lymph Node Syndrome
"Mucocutaneous Lymph Node Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
| Descriptor ID |
D009080
|
| MeSH Number(s) |
C14.907.940.560 C15.604.560 C17.800.862.560
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mucocutaneous Lymph Node Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Mucocutaneous Lymph Node Syndrome".
This graph shows the total number of publications written about "Mucocutaneous Lymph Node Syndrome" by people in this website by year, and whether "Mucocutaneous Lymph Node Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mucocutaneous Lymph Node Syndrome" by people in Profiles.
-
Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines. Pediatrics. 2022 12 01; 150(6).
-
Long-Term Impact of Hospitalization for Kawasaki Disease on Health-Related Quality of Life. Hosp Pediatr. 2022 03 01; 12(3):248-257.
-
Kawasaki Disease Substantially Impacts Health-Related Quality of Life. J Pediatr. 2018 02; 193:155-163.e5.
-
Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
-
Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
-
Modelling seasonal variations in the age and incidence of Kawasaki disease to explore possible infectious aetiologies. Proc Biol Sci. 2012 Jul 22; 279(1739):2736-43.
-
Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J. 2010 Aug; 69(8):194-7.
-
Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010 Jun; 29(6):483-8.
-
Evaluation of seasonal patterns of Kawasaki syndrome- and rotavirus-associated hospitalizations in California and New York, 2000-2005. BMC Pediatr. 2009 Oct 16; 9:65.
-
Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2009 May; 28(5):438-40.